TW201521746A - 用於減少鉀及治療慢性腎病及/或慢性心臟病之微孔矽酸鋯與利尿劑 - Google Patents

用於減少鉀及治療慢性腎病及/或慢性心臟病之微孔矽酸鋯與利尿劑 Download PDF

Info

Publication number
TW201521746A
TW201521746A TW103112757A TW103112757A TW201521746A TW 201521746 A TW201521746 A TW 201521746A TW 103112757 A TW103112757 A TW 103112757A TW 103112757 A TW103112757 A TW 103112757A TW 201521746 A TW201521746 A TW 201521746A
Authority
TW
Taiwan
Prior art keywords
value
ion
less
potassium
composition
Prior art date
Application number
TW103112757A
Other languages
English (en)
Chinese (zh)
Inventor
唐納 傑佛瑞 凱瑟
阿爾瓦羅 Ｆ 吉蘭
Original Assignee
Ｚｓ製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51654632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201521746(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ｚｓ製藥股份有限公司 filed Critical Ｚｓ製藥股份有限公司
Publication of TW201521746A publication Critical patent/TW201521746A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW103112757A 2013-04-05 2014-04-07 用於減少鉀及治療慢性腎病及/或慢性心臟病之微孔矽酸鋯與利尿劑 TW201521746A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808897P 2013-04-05 2013-04-05
US201361914362P 2013-12-10 2013-12-10
US201461930331P 2014-01-22 2014-01-22

Publications (1)

Publication Number Publication Date
TW201521746A true TW201521746A (zh) 2015-06-16

Family

ID=51654632

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103112757A TW201521746A (zh) 2013-04-05 2014-04-07 用於減少鉀及治療慢性腎病及/或慢性心臟病之微孔矽酸鋯與利尿劑

Country Status (21)

Country Link
US (3) US20160051584A1 (cg-RX-API-DMAC7.html)
EP (1) EP2981272B1 (cg-RX-API-DMAC7.html)
JP (1) JP6280636B2 (cg-RX-API-DMAC7.html)
KR (1) KR102308673B1 (cg-RX-API-DMAC7.html)
CN (1) CN105473151B (cg-RX-API-DMAC7.html)
AU (1) AU2014248081B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015025438B1 (cg-RX-API-DMAC7.html)
CA (1) CA2908641C (cg-RX-API-DMAC7.html)
CL (1) CL2015002951A1 (cg-RX-API-DMAC7.html)
DK (1) DK2981272T3 (cg-RX-API-DMAC7.html)
ES (1) ES2943007T3 (cg-RX-API-DMAC7.html)
FI (1) FI2981272T3 (cg-RX-API-DMAC7.html)
HU (1) HUE061862T2 (cg-RX-API-DMAC7.html)
IL (1) IL241926B (cg-RX-API-DMAC7.html)
MX (1) MX2015014055A (cg-RX-API-DMAC7.html)
PH (1) PH12015502301A1 (cg-RX-API-DMAC7.html)
PL (1) PL2981272T3 (cg-RX-API-DMAC7.html)
PT (1) PT2981272T (cg-RX-API-DMAC7.html)
TW (1) TW201521746A (cg-RX-API-DMAC7.html)
WO (1) WO2014165670A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507666B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106725A (zh) 2011-02-11 2019-01-01 Zs制药公司 用于治疗高钾血症的微孔性的硅酸锆
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN114917247B (zh) * 2022-05-18 2024-01-26 广东省疾病预防控制中心 纳米二氧化钛在防治肾损伤中的应用
CN117776193A (zh) * 2023-12-25 2024-03-29 杭州国瑞生物科技有限公司 一种环硅酸锆钠zs-9的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601398D0 (en) * 1996-01-24 1996-03-27 Piper Edwina M Composition
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
AU2000260501A1 (en) * 2000-07-12 2002-01-21 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US20040105895A1 (en) * 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) * 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
ES2939021T3 (es) * 2008-08-22 2023-04-18 Vifor Int Ltd Composiciones que comprenden polímeros reticulados de intercambio catiónico y uso en el tratamiento de la hipercalemia
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
CN109106725A (zh) 2011-02-11 2019-01-01 Zs制药公司 用于治疗高钾血症的微孔性的硅酸锆
AU2013290141A1 (en) 2012-07-11 2015-02-05 Alvaro F. Guillem Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
CN104797263B (zh) * 2012-10-22 2018-02-09 Zs制药公司 用于治疗高钾血症的微孔硅酸锆

Also Published As

Publication number Publication date
ES2943007T3 (es) 2023-06-08
BR112015025438B1 (pt) 2022-06-07
CA2908641C (en) 2022-10-18
DK2981272T3 (da) 2023-05-01
WO2014165670A1 (en) 2014-10-09
CL2015002951A1 (es) 2016-11-11
JP6280636B2 (ja) 2018-02-14
EP2981272A4 (en) 2016-12-07
US20180271902A1 (en) 2018-09-27
KR102308673B1 (ko) 2021-10-01
EP2981272A1 (en) 2016-02-10
PL2981272T3 (pl) 2023-05-29
CN105473151B (zh) 2018-09-18
US20140302175A1 (en) 2014-10-09
CN105473151A (zh) 2016-04-06
CA2908641A1 (en) 2014-10-09
IL241926B (en) 2020-10-29
MX2015014055A (es) 2015-12-15
PT2981272T (pt) 2023-05-03
US20160051584A1 (en) 2016-02-25
PH12015502301A1 (en) 2016-02-10
FI2981272T3 (fi) 2023-05-03
AU2014248081B2 (en) 2019-02-28
BR112015025438A2 (pt) 2017-07-18
HK1221177A1 (en) 2017-05-26
HUE061862T2 (hu) 2023-08-28
KR20150140750A (ko) 2015-12-16
EP2981272B1 (en) 2023-03-01
JP2016515624A (ja) 2016-05-30
ZA201507666B (en) 2019-09-25
US10695366B2 (en) 2020-06-30
AU2014248081A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
CN104797263B (zh) 用于治疗高钾血症的微孔硅酸锆
CA2929978C (en) Microporous zirconium silicate for the treatment of hyperkalemia
US20160375054A1 (en) Microporous Zirconium Silicate for the Treatment of Hyperkalemia
US10695366B2 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
US20160038538A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
US20150359821A1 (en) Microporous Zirconium Silicate for the Treatment of Hyperkalemia
HK40112785A (en) Microporous zirconium silicate for the treatment of hyperkalemia
TWI655948B (zh) 用於高血鉀治療之微孔矽酸鋯
KR20160096178A (ko) 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄
HK1231745A1 (zh) 用於治疗高钾血症的微孔硅酸锆
HK1231745B (zh) 用於治疗高钾血症的微孔硅酸锆
HK1221177B (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease